Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback